DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xsk3w5/relapsed) has announced the addition of Global Markets Direct's new report "Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
Scope
- A snapshot of the global therapeutic scenario for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
- A review of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- News and deals relating to the products.
Reasons to Buy
- Identify and understand important and diverse types of therapeutics under development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/xsk3w5/relapsed
Source: Global Markets Direct